Skip to main content
. 2022 Dec 28;56:101809. doi: 10.1016/j.eclinm.2022.101809

Table 1.

Demographic information of N = 52 participants.

Psilocybin (N = 26) Placebo (N = 26)
Age 37.6 (10.9) 35.9 (9.80)
Verbal IQ 115 (13.1) 113 (12.1)
Years of education 14.4 (2.52) 15.0 (2.39)
Gender
 Female 16 (61.5%) 17 (65.4%)
 Male 10 (38.5%) 9 (34.6%)
Ethnicity
 White 26 (100%) 23 (88.4%)
 Black Caribbean 0 (0%) 1 (3.8%)
 Arab 0 (0%) 2 (7.7%)
Clinical
 MADRS [0–60] 24.3 (5.07) 24.1 (7.07)
 BDI [0–63] 26.9 (6.70) 25.8 (9.59)
 CGI Severity [2–8] 5.50 (0.58) 5.54 (0.91)
 Suicidal ideation [0–5] 0.53 (0.85) 0.46 (0.65)
Meds at baseline
 Mean (SD) # antidepressants 0.42 (0.90) 0.27 (0.45)
 # of participants with 0 19 (73%) 19 (73%)
 # of participants with 1 5 (19%) 7 (27%)
 # of participants with >1 2 (7.7%) 0 (0.0%)
 Mean (SD) # prescription meds 0.69 (0.93) 0.38 (0.70)
 # of participants with 0 14 (54%) 19 (73%)
 # of participants with 1 8 (31%) 4 (15%)
 # of participants with >1 4 (15%) 3 (12%)
Prior psychedelic experiences
 # of participants with prior experience 5 (19.2%) 11 (42.3%)
 Mean (SD) life-time occassions with a psychedelic agent from pre-experienced individuals 2.40 (1.52) 2.00 (1.00)

Verbal IQ was assessed by the Multiple-Choice Word Test (MWT-B). Clinical Global Impressions (CGI) provides a clinician-rated impression of overall severity of clinical symptomatology. Suicidal ideation is derived from the intensity of ideation subscale from the Colombia Suicidality Severity Rating Scale (C-SSRS) assessing suicidal thoughts with a scale ranging from zero to five whereas scores greater than three imply acute intentionality. The number of medications used was assessed at the medical screening before discontinuation. Prescription medications include all pharmaceuticals only available on prescription, excluding antidepressant medication which is reported separately. Percentages may not sum up to 100% due to rounding.